Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13
HOS-142660 · Präparat HOS-098846
Description of selected adverse drug reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage f29256a6bc431f1ad051b701d8fb1dc2da9c50bcdd7b10ef2e3e7984e9ef3bd0 · Zeichen 5301–5347 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13
HOS-142661 · Präparat HOS-098846
Myelosuppression
In a placebo-controlled study GO39942 (POLARIX), 0.5% of patients in the Polivy plus R-CHP arm
discontinued study treatment due to neutropenia. No patients discontinued study treatment in the R-
CHOP arm due to neutropenia. Thrombocytopenia events led to discontinuation of study treatment in
0.2% of patients in the Polivy plus R-CHP arm compared to no patients in the R-CHOP arm. No
patients discontinued treatment due to anaemia in either the Polivy plus R-CHP arm or R-CHOP arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 8431219eef55b30b517a400370f4c273d769f1e7f9f63e82a416aaf9a2d668c4 · Zeichen 5349–5848 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13
HOS-142662 · Präparat HOS-098846
In an open-label study GO29365, 4% of patients in the Polivy plus BR arms discontinued Polivy due
to neutropenia compared to 2.6% of patients in the BR arm who discontinued treatment due to
neutropenia. Thrombocytopenia events led to discontinuation of treatment in 7.9% of patients in the
Polivy plus BR arms and 5.1% of patients in the BR arm. No patients discontinued treatment due to
anaemia in either the Polivy plus BR arms or BR arm. In the Polivy plus BR arms, Grade 3 or higher
neutropenia, thrombocytopenia, and anaemia were reported in 40.4%, 25.8%, and 12.6% of patients,
respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 2c68f5734b20570be2e279be86852a8b8507bead06a9b2516d9120c5580227b0 · Zeichen 5850–6447 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13
HOS-142663 · Präparat HOS-098846
Peripheral neuropathy (PN)
In a placebo-controlled study GO39942 (POLARIX), in the Polivy plus R-CHP arm, Grade 1, 2, and 3
PN were reported in 39.1%, 12.2% and 1.6% of patients, respectively. In the R-CHOP arm, Grade 1, 2
and 3 PN events were reported in 37.2%, 15.5% and 1.1% of patients, respectively. No Grade 4-5 PN
events were reported in either the Polivy plus R-CHP arm or R-CHOP arm. 0.7% of patients
discontinued study treatment in the Polivy plus R-CHP arm due to PN compared to 2.3% in the R-
CHOP arm. 4.6% of patients in the Polivy plus R-CHP arm had study treatment dose reduction due to
PN compared to 8.2% in the R-CHOP arm. In the Polivy plus R-CHP arm, the median time to onset of
first event of PN was 2.27 months compared to 1.87 months in the R-CHOP arm. PN events resolved
in 57.8% of patients in the Polivy plus R-CHP arm as of the clinical cut off date compared to 66.9% in
the R-CHOP arm. The median time to peripheral neuropathy resolution was 4.04 months in the Polivy
plus R-CHP arm compared to 4.6 months in the R-CHOP arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage a2e1f97a4a3cd380ff564b1425e657ff78f5c012bbb4e1b7c4a5023dcbca63d2 · Zeichen 6449–7502 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13
HOS-142664 · Präparat HOS-098846
In an open-label study GO29365, in the Polivy plus BR arms, Grade 1 PN and Grade 2 PN were
reported in 15.9% and 12.6% of patients, respectively. In the BR arm, Grade 1 and 2 PN events were
reported in 2.6% and 5.1% of patients, respectively. One Grade 3 PN event was reported in the Polivy
plus BR arms and no patients reported PN events in the BR arm. No Grade 4-5 PN events were
reported in either the Polivy plus BR arms or BR arm. 2.6% of patients discontinued Polivy treatment
due to PN and 2.0% of patients had Polivy dose reduction due to PN. No patients in the BR arm
discontinued treatment or had dose reductions due to PN. In the Polivy plus BR arms, the median time
to onset of first event of PN was 1.6 months, and 39.1% of patients with PN events reported event
resolution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 25daa1b7429895e50e8d39ada1bd9a50b0904d7b8b4a2c3d1c0b0982b811107e · Zeichen 7504–8291 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13
HOS-142665 · Präparat HOS-098846
Infections
In a placebo-controlled study GO39942 (POLARIX), infections, including pneumonia and other types
of infections, were reported in 49.7% of patients in the Polivy plus R-CHP arm and 42.7% of patients
in the R-CHOP arm. Grade 3-4 infections occurred in 14.0% of patients in the Polivy plus R-CHP arm
and 11.2% of patients in the R-CHOP arm. In the Polivy plus R-CHP arm, serious infections were
reported in 14.0% of patients and fatal infections were reported in 1.1% of patients. In the R-CHOP
arm, serious infections were reported in 10.3% of patients and fatal infections were reported in 1.4%
of patients. 7 patients (1.6%) in the Polivy plus R-CHP arm discontinued treatment due to infection
compared to 10 patients (2.3%) in the R-CHOP arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage c51d69368dbac99c6e154b2f60a44083e75856dd24cb94ef076c7122bda94bef · Zeichen 8293–9047 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 13–14
HOS-142666 · Präparat HOS-098846
13
In an open-label study GO29365, infections, including pneumonia and other types of infections, were
reported in 48.3% of patients in the Polivy plus BR arms and 51.3% of patients in the BR arm. In the
Polivy plus BR arms, serious infections were reported in 27.2% of patients and fatal infections were
reported in 6.6% of patients. In the BR arm, serious infections were reported in 30.8% of patients and
fatal infections were reported in 10.3% of patients. Four patients (2.6%) in the Polivy plus BR arms
discontinued treatment due to infection compared to 2 patients (5.1%) in the BR arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 7b5cb24369f74729e0c6c82dbf5637ef4553e382b060353ab7a9a274d05ceba2 · Zeichen 9101–9695 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142667 · Präparat HOS-098846
Progressive multifocal leukoencephalopathy (PML)
In a placebo-controlled study GO39942 (POLARIX), no cases of PML were reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage c5774492856045c771bbc8ea06a1336a0f68db82ad7a44c5d2715543fecc7aca · Zeichen 9697–9825 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142668 · Präparat HOS-098846
In an open-label study GO29365, one case of PML, which was fatal, occurred in one patient treated
with Polivy plus bendamustine and obinutuzumab. This patient had three prior lines of therapy that
included anti-CD20 antibodies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 9996a7f8d2968ac04bfc8bbcb45923667341ae5360bfb20852cc4cd631c1b3a9 · Zeichen 9827–10054 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142669 · Präparat HOS-098846
Hepatic toxicity
In a placebo-controlled study GO39942 (POLARIX), hepatic toxicity was reported in 10.6% of
patients in the Polivy plus R-CHP arm and 7.3% of patients in the R-CHOP arm. In the Polivy plus R-
CHP arm, most events were Grade 12 (8.7%); Grade 3 events were reported in 1.8% of patients.
There were no Grade 4 or 5 events. Serious hepatic toxicity events were reported in 1 patient (0.2%)
and were reversible.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 9334b7816f0d42c8b1ba58123c8927a59946dbbb012ea150fa08f7c748bfec3a · Zeichen 10056–10479 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142670 · Präparat HOS-098846
In another study, two cases of serious hepatic toxicity (hepatocellular injury and hepatic steatosis)
were reported and were reversible.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage b2166f229cdbeb9c36512890a1f66bef8b1b3ba20dbe5f37f75c3f1cad57fd37 · Zeichen 10481–10617 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142671 · Präparat HOS-098846
Gastrointestinal toxicity
In a placebo-controlled study GO39942 (POLARIX), gastrointestinal toxicity events were reported in
76.1% of patients in the Polivy plus R-CHP arm compared to 71.9% of patients in the R-CHOP arm.
Most events were Grade 1–2, and Grade 3 events were reported in 9.7% of patients in the Polivy plus
R-CHP arm compared to 8.2% of patients in the R-CHOP arm. The most common gastrointestinal
toxicity events were nausea and diarrhoea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage be19f8e3de160ade074ff2955df65ed534edeb15926c338eee526c19842d0ff4 · Zeichen 10619–11074 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142672 · Präparat HOS-098846
In an open-label study GO29365, gastrointestinal toxicity events were reported in 72.8% of patients in
the Polivy plus BR arms compared to 66.7% of patients in the BR arm. Most events were Grade 1-2,
and Grade 3-4 events were reported in 16.5% of patients in the Polivy plus BR arms compared to
12.9% of patients in the BR arm. The most common gastrointestinal toxicity events were diarrhoea
and nausea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 7aa3e6e3907612ed02eec6fbaa1f43edc56f50f99839d66b473df63565af2373 · Zeichen 11076–11479 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142673 · Präparat HOS-098846
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 11481–11521 im Abschnitt
Nebenwirkungen · Polivy
Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 14
HOS-142674 · Präparat HOS-098846
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:17:00Z · SHA-256 a3e89d92646e20e619974ca0dc3eec49e6a7f37bd13a6556343aef72032c4fc0 · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 11523–11837 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.